NCT00002014已完成1 期
A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)
Glaxo Wellcome8 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 试验地点
- 8
研究概览
简要总结
To determine the safety and tolerance of various combinations of zidovudine (AZT) and didanosine (ddI) administered concurrently. To determine the pharmacokinetics of concurrent AZT and ddI administered orally. To evaluate the antiviral, immunologic and virologic effects of AZT and ddI administered concurrently.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Acyclovir not to exceed two 14-day courses of therapy during trial. Discontinue ddI while receiving acyclovir.
- •Patients must have the following:
- •Positive HIV antibody using federally licensed ELISA test kit.
- •CD4 counts < 400 on two consecutive visits within one month prior to entry.
- •Prior Medication:
- •Zidovudine (AZT) if treated for less than 120 days.
- •Pharmacologic doses of steroids if given for management of Pneumocystis carinii pneumonia (PCP) (not to exceed 21 days).
排除标准
- •Co-existing Condition:
- •Patients with the following conditions or symptoms are excluded:
- •- Visceral or progressive Kaposi's sarcoma (KS) (defined by > 10 new lesions in the thirty days prior to entry) or patients who require chemotherapy or radiation therapy for Kaposi's sarcoma. Other concurrent neoplasms other than basal cell carcinoma of skin or in situ carcinoma of the cervix. Malabsorption as defined by persistent diarrhea ( > 4 stools/day for four weeks) which is unresponsive to antidiarrheal agents. Opportunistic infection requiring maintenance therapy. History of Central Nervous System opportunistic infections (e.g., toxoplasmosis, cryptococcosis). History of seizure disorders. Prior history of pancreatitis. History of peripheral neuropathy or any significant signs or symptoms of neurological disease. Examinations for peripheral neuropathy should assess changes in extremities. Clinically significant hyperuricemia (tophaceous gout, urate nephropathy). History of cardiomyopathy.
- •Concurrent Medication:
- •Intravenous pentamidine.
- •Intravenous trimethoprim / sulfamethoxazole.
- •Suppressive acyclovir therapy (see Inclusion Medications).
- •Allopurinol.
- •Probenecid.
- •Isoniazid (INH).
- •Dipyridamole.
- •Concurrent Treatment:
- •Radiation therapy for Kaposi's sarcoma.
- •Patients with the following are excluded:
- •Zidovudine (AZT) intolerance as evidenced by inability to tolerate at least 600 mg AZT daily.
- •Previously intolerant to didanosine (ddI) evidenced by peripheral neuropathy or seizures or pancreatitis or gastrointestinal toxicity or hematologic toxicity.
- •Diseases or conditions listed under Patient Exclusion Co-existing Conditions.
- •Prior Medication:
- •Zidovudine (AZT) for > 120 days.
- •Dideoxycytidine (ddC).
- •Excluded within 30 days of study entry:
- •Antiretroviral therapy.
- •Immunomodulators.
- •Biological response modifiers.
- •Cytotoxic chemotherapy for Kaposi's sarcoma.
- •Excluded within 60 days of study entry:
- •Ribavirin.
- •Prior Treatment:
- •Excluded within 2 weeks of study entry:
- •Transfusions.
- •Excluded within 30 days of study entry:
- •Radiation therapy for Kaposi's sarcoma.
- •Active substance abuse that would impair compliance with study procedures.
研究者
研究点 (8)
Loading locations...
相似试验
已完成
1 期
A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV InfectionHIV InfectionsNCT00000652National Cancer Institute (NCI)85
已完成
2 期
A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and DidanosineHIV InfectionsNCT00000770National Institute of Allergy and Infectious Diseases (NIAID)400
已完成
2 期
A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3HIV InfectionsNCT00000625National Institute of Allergy and Infectious Diseases (NIAID)2,100
已完成
2 期
A Study of Dideoxycytidine Plus Zidovudine (AZT) in HIV-Infected Children Who Have Taken AZTHIV InfectionsNCT00001032National Institute of Allergy and Infectious Diseases (NIAID)180
已完成
2 期
A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)HIV InfectionsNCT00000781National Institute of Allergy and Infectious Diseases (NIAID)1,292